Closing the HPV Testing Gap Act
- Sponsor
- Rep. McIver, LaMonica [D-NJ-10]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- May 20, 2026
Bottom line
The "Closing the HPV Testing Gap Act" mandates an NIH study to advance the development and implementation of noninvasive HPV testing for men, aiming to address a critical public health gap and promote gender equity in cancer prevention.
What it actually does
This bill directs the Director of the National Institutes of Health (NIH) to conduct a comprehensive study on the development of a standardized, noninvasive test for Human Papillomavirus (HPV) in men. The study must assess current research, explore testing methodologies, consider implementation strategies, and recommend interagency coordination for regulatory approval and equitable access. NIH is also required to establish an interagency working group and submit a report to Congress within 30 months of enactment detailing findings and recommendations.
Proponents argue
Supporters argue that this bill is crucial for closing a significant public health gap, as there is currently no FDA-approved HPV diagnostic test for men, despite men experiencing a significant proportion of HPV-related cancers, particularly oropharyngeal cancers. They contend that expanding HPV detection to men will enhance national cancer control, promote gender equity in prevention, and reduce sustained transmission pathways that impact women's health outcomes, including cervical cancer incidence.
Opponents contend
Critics might argue that while the goal is laudable, directing NIH to conduct a specific study via legislation could be seen as micromanaging scientific research priorities, potentially diverting resources from other pressing public health issues or research areas that NIH scientists deem more critical or ready for investment. Some might also raise concerns about the potential costs associated with developing and implementing widespread male HPV testing, even if the study itself uses existing funds.
The bill is very short and clear, making it highly accessible for any reader to understand its core directives and purpose.
Section 3(a)
Directing NIH to Study Standardized, Noninvasive HPV Test for Men
This provision requires the Director of the National Institutes of Health (NIH) to conduct a comprehensive study within 24 months of the bill's enactment. The study's focus is on developing a standardized, noninvasive test for Human Papillomavirus (HPV) in men, addressing a current gap in diagnostic capabilities.
Supporters argue
Supporters argue this mandate is essential to address the critical public health need for male HPV testing, which currently lacks an FDA-approved diagnostic. They believe it will spur necessary research to improve cancer prevention and health equity.
Critics contend
No specific opposition is typically raised against the concept of studying disease detection. Potential concerns might revolve around resource allocation if it is perceived to detract from other research priorities, but not against the study itself.
Tradeoffs
The primary tension is balancing this specific research directive with NIH's broader research portfolio and ensuring that the study is conducted efficiently and effectively without undue diversion of resources from other critical areas.
Section 3(b), 3(c)
Defining Study Consultations, Coordination, and Elements
This section outlines how the NIH study must be conducted, requiring consultation with key federal health agencies (CDC, FDA, HRSA) and the National Academy of Medicine, as well as scientific experts. It specifies that the study must assess current knowledge, explore various noninvasive testing methodologies (including multi-site testing like oral, anal, and urine), provide implementation considerations for future testing protocols, and develop recommendations for interagency coordination to facilitate regulatory approval and equitable access.
Section 3(d), 3(e)
Interagency Working Group and Congressional Reporting Requirements
This provision mandates the NIH Director to establish an interagency working group, including representatives from the FDA, CDC, HRSA, and the National Academy of Medicine, to ensure coordinated implementation of the study across scientific, regulatory, and community pathways. Furthermore, it requires the NIH Director to submit a report to Congress within 30 months of enactment, detailing the study's findings, conclusions, recommendations for developing and implementing male HPV tests, and strategies for integrating testing into national cancer prevention and health equity initiatives.
Directs the NIH Director to use existing funds for the study, rather than authorizing new appropriations.
Section 3(g)
Why it matters:This is standard legislative practice for bills that aim to direct agency activity without increasing the federal budget deficit, making it more palatable for passage. It avoids the need for new spending authorizations.
Case for: Supporters would argue this demonstrates fiscal responsibility, ensuring the study proceeds without increasing federal spending, making it more likely to gain bipartisan support.
Case against: Critics might contend that relying solely on existing funds could strain NIH's budget, potentially requiring reallocation from other important research areas or limiting the scope and depth of the HPV study if sufficient existing funds are not readily available.
Estimated impact: The impact is that the study's costs will be absorbed within NIH's current or future appropriated budgets, rather than being an additional federal expenditure.